Identifying outcome measures for clinical trials in juvenile idiopathic arthritis associated uveitis for the MIWGUC proposal: a scoping review to create domains from existing outcome measures
Authors' conclusion
Our review confirms the variety of outcome measures for JIA-U while highlighting the emergence of novel imaging and biomarker-based measures.
Study context
- Population
- Studies investigating outcome measures used in Juvenile Idiopathic Arthritis (JIA)-associated uveitis (JIA-associated uveitis (JIA-U)), 1 January 2019 to 28 February 202537 studies plus previous 27
- Outcome
- Outcome measures used in JIA-U: similarities, differences and emerging outcome domains
Methodological detailssystematic literature review, PRISMA guidelines, update of the 2019 systematic literature review, 261 papers identified, 90 potentially eligible
- Systematic literature review
- PRISMA guidelines
- Update of the 2019 systematic literature review
- 261 papers identified, 90 potentially eligible
Main finding
As reported in the abstract
Outcome measures for JIA-U
- Outcome measures identified
- 15
- Disease activity outcome measures (studies)
- 30
- Structural damage outcome measures (studies)
- 29
- Severe disease course outcome measures (studies)
- 20
- Anterior chamber (AC) cells (studies)
- 29
- Visual acuity (studies)
- 21
- Development of structural complications (studies)
- 20
- Use and sparing of immunosuppressive therapies (studies)
- 15
- Studies reporting novel objective techniques for inflammation assessment (laser flare photometry, anterior segment optical coherence tomography), vs 2019 review
- 4
Original publication
Identifying outcome measures for clinical trials in juvenile idiopathic arthritis associated uveitis for the MIWGUC proposal: a scoping review to create domains from existing outcome measures. Pediatr Rheumatol Online J. Published 25 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →